EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ivonescimab: First Approval

Sohita Dhillon

Drugs · 2024

DOI: 10.1007/s40265-024-02073-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Sohita Dhillon. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Drug Approval. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ivonescimab (®) is a first-in-class, humanized, tetravalent bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF)-A being developed by Akeso Biopharma for the treatment of non-small cell lung cancer (NSCLC) and other solid tumours, including breast cancer, liver cancer and gastric cancer. Ivonescimab simultaneously blocks the binding of PD-1 to its ligand (PD-L1), thereby relieving PD-1/PD-L1-mediated immunosuppression, and blocks the binding of VEGF-A to its receptor (VEGFR2), thus blocking tumour angiogenesis in the tumour microenvironment. In May 2024, ivonescimab, in combination with pemetrexed and carboplatin, received its first approval in China for the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have progressed after tyrosine kinase inhibitor (TKI) therapy. Clinical studies of ivonescimab are underway in multiple countries worldwide. This article summarizes the milestones in the development of ivonescimab leading to this first approval for EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have progressed after TKI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedDrug ApprovalHumansVascular Endothelial Growth Factor AProgrammed Cell Death 1 ReceptorAntibodies, BispecificErbB ReceptorsB7-H1 AntigenPemetrexedCarboplatinAntineoplastic Combined Chemotherapy ProtocolsVascular Endothelial Growth Factor Receptor-2

Substanzen

Antibodies, Monoclonal, HumanizedVascular Endothelial Growth Factor AProgrammed Cell Death 1 ReceptorAntibodies, BispecificErbB ReceptorsB7-H1 AntigenPemetrexedCarboplatinPDCD1 protein, humanCD274 protein, human

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Dhillon, S. (2024). Ivonescimab: First Approval. Drugs. https://doi.org/10.1007/s40265-024-02073-w

Vancouver

Dhillon S. Ivonescimab: First Approval. Drugs. 2024. doi:10.1007/s40265-024-02073-w

BibTeX
@article{Dhillon2024,
  author = {Dhillon, Sohita},
  title = {Ivonescimab: First Approval},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-024-02073-w}
}
Kostenlos starten →